

IMPAKT CONFERENCE PROGRAMME

Thursday, 2 May 2013

**10:45/
11:45** **IMPAKT 2013 Press conference** **PRESS CENTRE**

**11:30/
12:00** **Lunch for Satellite attendees**

**12:00/
13:00** **Latest clinical advances and
biomarker research in HER2-positive
breast cancer** **SILVER HALL**
Roche Satellite Symposium
Please refer to page 43 for details

**13:15/
13:25** **Official Welcome** **GOLD HALL**

13:15 Programme overview and main themes of IMPAKT 2013
Peter Dubsy, Vienna, Austria, Martine Piccart, Brussels, Belgium
and Andrew Tutt, London, UK

**13:25/
14:15** **Opening Keynote Lecture** **GOLD HALL**
Moderator: Martine Piccart, Brussels, Belgium

13:25 Integrating breast cancer genomics and proteomics -
shooting for the moon
Gordon Mills, Houston, TX, US

14:05 Q&A

**14:15/
15:15** **Heterogeneity in breast cancer
captured by DNA and RNA sequencing:
What does it mean to clinician and patient?** **GOLD HALL**
Moderators: Larry Norton, New York, NY, US
and Jorge Reis-Filho, New York, NY, US

14:15 The METABRIC consortium 2000 Breast Cancer Study:
An update
Carlos Caldas, Cambridge, UK

14:35 The Cancer Genome Atlas (TCGA) comprehensive molecular
portraits of breast cancer
Charles M. Perou, Chapel Hill, NC, US

14:55 Moderated audience discussion: What does it mean
to clinician and patient?
Larry Norton, New York, NY, US
and Jorge Reis-Filho, New York, NY, US

15:15	Break	
15:30/ 17:10	Heterogeneity of breast cancer: How much is there at the start and how much happens over time? Moderators: Angelo Di Leo, Prato, Italy and Charles Swanton, London, UK	GOLD HALL
15:30	A historical perspective of intratumour heterogeneity in breast cancer Charles Swanton, London, UK	
15:45	Single cell sequencing techniques in early and late breast cancer Nicholas Navin, Houston, TX, US	
16:00	How do we understand cancer's genomic heterogeneity at different distant sites? Peter Campbell, Cambridge, UK	
16:15	Discussion of heterogeneity from the aspect of tumour evolution and new approaches to clinical trials Robert A. Gatenby, Tampa, FL, US	
16:30	400_PR - Contribution of analytical, pre-analytical and intra-tumoural heterogeneity to variance in gene expression measurements from human breast cancers Rosanna Lau, Houston, TX, US	
16:37	410_PR - Heterogeneity of genomic signatures in breast cancer core biopsy Michal Jarzab, Gliwice, Poland	
16:44	Discussant abstracts 400_PR and 410_PR Jorge Reis-Filho, New York, NY, US	
16:55	General Q&A	
17:10	Coffee Break	
17:30/ 19:00	Can host immune response beat tumour heterogeneity or does it complicate outcomes? Moderators: Axel Rody, Luebeck, Germany and Veronika Sexl, Vienna, Austria	GOLD HALL
17:30	The breast cancer immune stromal interface: Can the lab tell us who is at the meeting and what is the conversation? Veronika Sexl, Vienna, Austria	
17:50	Q&A	
17:55	Is there evidence from the clinic that the immune system influences outcomes in breast cancer? Sherene Loi, Melbourne, Australia	
18:15	Q&A	

- 18:20 Moderated panel discussion: How should immunobiologists and clinical researchers develop immunotherapeutic and biomarker strategies for breast cancer?
Axel Rody, Luebeck, Germany
and Veronika Sexl, Vienna, Austria
- 18:40 **840** - CXCL13-producing follicular helper CD4+ T Cells in extensively-infiltrated breast cancer signal an organized immune response and predict survival
Karen Willard-Gallo, Brussels, Belgium
- 18:47 Discussant abstract 840
Giuseppe Curigliano, Milan, Italy
- 18:52 General Q&A

19:00 Welcome Reception

GOLD FOYER

Friday, 3 May 2013

08:30/ **Keynote Lecture**

GOLD HALL

09:00

Moderator: Martine Piccart, Brussels, Belgium

08:30

Targeting the PI3K/AKT/mTOR axes in breast cancer:
A new dawn?
Maurizio Scaltriti, New York, NY, US

09:00/
10:25

**PI3K/AKT/mTOR: Targets/trials
and biomarkers. An horizon scan
and debate**

GOLD HALL

Moderators: Fabrice André, Villejuif, France and
Maurizio Scaltriti, New York, NY, US

09:00

PI3K alpha specific or general inhibitors
Dejan Juric, Boston, MA, US

09:20

Biomarker analyses in emerging data from PI3K/AKT/mTOR
programme clinical trials
Ana Vivancos, Barcelona, Spain

09:40

560_PR - Predictive value of AKT/mTOR pathway
immunohistochemical (IHC) biomarkers for response to
preoperative trastuzumab (T) vs trastuzumab + everolimus
(T+E) in patients (pts) with early breast cancer (BC):
Unicancer RADHER trial results
Mario Campone, St. Herblain, France

09:47

420_PR - Assessment of genetic alterations in
postmenopausal women with hormone receptor-positive,
HER2-negative advanced breast cancer from the BOLERO-2
trial by next-generation sequencing
Martine Piccart, Brussels, Belgium

09:54 Moderated panel discussion: How to optimize patient selection, patient settings (early or late) and target inhibition combinations in PI3K/AKT/mTOR trial design
Ana Vivancos, Barcelona, Spain
and Cristian Massacesi, Rueil-Malmaison-Paris, France

10:14 General Q&A

10:25 Break

10:45/12:15 **Best Abstracts session** **GOLD HALL**
Moderators: Peter Dubsy, Vienna, Austria
and Andrew Tutt, London, UK

10:45 **530_PR** - Predicting risk for late metastasis: The PAM50 risk of recurrence (ROR) score after 5 years of endocrine therapy in postmenopausal women with HR+ early breast cancer: A study on 1,478 patients from the ABCSG-8 trial
Michael Gnant, Vienna, Austria

10:52 Q&A from audience

10:55 **540_PR** - Comparison of five different scores for the prediction of late recurrence for oestrogen receptor-positive breast cancer
Ivana Sestak, London, UK

11:02 Q&A from audience

11:05 **550_PR** - Prognostic and predictive value of IHC4 and ERb1 in the Intergroup Exemestane Study (IES) - On behalf of the PathIES Investigators
Giuseppe Viale, Milan, Italy

11:12 Q&A from audience

11:15 Discussant abstracts 530_PR, 540_PR and 550_PR
W. Fraser Symmans, Houston, TX, US

11:25 Q&A from audience

11:30 **890** - Use of live in-vivo lymphatic imaging techniques to study the effects of immune cell interactions in a syngeneic mouse model of breast cancer
Sheeba Irshad, London, UK

11:37 Q&A from audience

11:40 **900** - GE226: A molecular targeted PET imaging agent to assess HER2 status in vivo
Duncan Hiscock, Amersham, UK

11:47 Q&A from audience

11:50 **910** - Early effect of PI3K-Akt-mTOR blockade on in vitro 18F-FDG uptake in HER2+ breast cancer resistant to trastuzumab
Yanina Dockx, Edegem, Belgium

- 11:57 Q&A from audience
- 12:00 Discussant abstracts 890, 900 and 910
Peter Brader, Vienna, Austria
- 12:10 Q&A from audience
-

**12:15/
13:15** **A new era in targeting multiple pathways in advanced breast cancer** **SILVER HALL**
prIME Oncology Satellite Symposium
Please refer to page 44 for details

13:15 Lunch

**13:45/
15:15** **Barriers to patient access for molecular diagnostics** **GOLD HALL**
Sividon, Nanostring, Genomic Health, Agendia,
Satellite Symposium
Please refer to page 45 for details

**15:25/
16:45** **Single target drug induced cancer rewiring: Is it a problem and can we predict and inhibit cancer reprogramming in the clinic?** **GOLD HALL**
Moderators: David Cameron, Edinburgh, UK
and Neal Rosen, New York, NY, US

15:25 What have we learnt from the model systems?
Gary Johnson, Chapel Hill, NC, US

15:40 Q&A

15:45 What is the evidence that this is a wider problem we need to address in the clinic?
Neal Rosen, New York, NY, US

16:00 Q&A

16:05 How do we design trials that improve outcome?
Lisa Carey, Chapel Hill, NC, US

16:20 Q&A

16:25 Moderated panel and audience discussion
David Cameron, Edinburgh, UK,
Lisa Carey, Chapel Hill, NC, US
and Neal Rosen, New York, NY, US

**16:45/
17:30** **Tea and Poster Walk** **GOLD FOYER**
Please refer to page 30 for details

17:30/ 18:30	Dissemination and organ specific metastasis of breast cancer: How does heterogeneity play a role? Moderators: Michael Gnant, Vienna, Austria and Roger Gomis, Barcelona, Spain	GOLD HALL
17:30	Extracellular matrix proteins of stem cell niches promote breast cancer metastasis Thordur Oskarsson, Heidelberg, Germany	
17:45	Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content Speaker: Salvatore Pece, Milan, Italy	
18:00	How do clinicians target the host at metastatic sites? Michael Gnant, Vienna, Austria	
18:15	Moderated audience discussion Roger Gomis, Barcelona, Spain	

Saturday, 4 May 2013

08:30/ 09:00	Design of biomarker driven neoadjuvant trials Moderators: Sibylle Loibl, Neu-Isenburg, Germany and Gunter von Minckwitz, Neu Isenburg, Germany	GOLD HALL
08:30	Design of biomarker driven neoadjuvant trials Sibylle Loibl, Neu-Isenburg, Germany	
08:50	Q&A	
09:00/ 10:30	Can heterogeneity in advanced breast cancer be captured by molecular imaging? Moderators: Peter Brader, Vienna, Austria and Gary Cook, London, UK	GOLD HALL
09:00	Novel molecular imaging of drug targets such as HER2, ER and VEGF Elisabeth de Vries, Groningen, Netherlands	
09:20	Monitoring bone disease FDG, fluoride and diffusion weighted MRI Gary Cook, London, UK	
09:40	Advanced MRI in breast cancer Katja Pinker-Domenig, Vienna, Austria	
10:00	Preclinical breast imaging Peter Brader, Vienna, Austria	
10:20	General Q&A	

10:30	Coffee break	
11:00/ 11:30	Susan G. Komen for the Cure® award session	GOLD HALL
11:30/ 13:00	Debate: In a world of BC heterogeneity is the biopsy of metastasis helpful or distracting? Moderators: Jonas Bergh, Stockholm, Sweden and Angelo Di Leo, Prato, Italy	GOLD HALL
11:30	Audience vote	
11:35	A) Clinician view pro Alastair Thompson, Dundee, UK	
11:55	Aa) Biologist view con Charles Swanton, London, UK	
12:15	B) Clinician view con Fabrice André, Villejuif, France	
12:35	Bb) Biologist view pro Peter Campbell, Cambridge, UK	
12:55	Audience vote	
13:00/ 13:30	Closing remarks Peter Dubsy, Vienna, Austria and Andrew Tutt, London, UK	GOLD HALL

INDUSTRY SATELLITE SYMPOSIUM

Thursday, 2 May 2013

**12:00/
13:00**

ROCHE

SILVER HALL

**Latest clinical advances and biomarker
research in HER2-positive breast cancer**

Chair: Martine Piccart, Brussels, Belgium

12:00

The next wave of successful drug therapy strategies
in HER2-positive breast cancer
Hans Wildiers, Leuven, Belgium

12:20

Is there a place for other biomarkers beyond HER2
in HER2-positive breast cancer?
Astrid Kiermaier, Basel Switzerland

12:40

Roundtable discussion
Fabrice André, Villejuif, France,
Luc Dirix, Antwerp, Belgium,
Sherene Loi, Melbourne, Australia,
Gordon Mills, Houston, TX, US,
and Jorge Reis-Filho, New York, NY, US



INDUSTRY SATELLITE SYMPOSIUM

Friday, 3 May 2013

12:15/
13:15

prIME ONCOLOGY SUPPORTED
BY NOVARTIS ONCOLOGY

SILVER HALL

**A new era in targeting multiple pathways
in advanced breast cancer**

Chair: Sunil Verma, Toronto, ON, Canada

12:15

Inhibiting crosstalk between ER and PI3K/AKT/mTOR
pathways: What we know and what we would like to know
Nicholas Turner, London, UK

12:30

Challenging patient scenarios from clinical practice
Sunil Verma, Toronto, ON, Canada

13:00

What does the future hold for PI3K/AKT/mTOR inhibitors
in breast cancer?
Sara Hurvitz, Los Angeles, CA, US

Support for this educational activity
is provided by Novartis Oncology



INDUSTRY SATELLITE SYMPOSIUM

**13:45/
15:15**

**AGENDIA, GENOMIC HEALTH,
NANOSTRING AND
SIVIDON DIAGNOSTICS**

GOLD HALL

It's time to enable patient access for molecular diagnostics

Chairs: Martine Piccart, Brussels, Belgium
and Sherene Loi, Melbourne, Australia

- 13:45 It's time to enable patient access for well-validated molecular diagnostics
Martine Piccart, Brussels, Belgium
- 13:55 Evidence supporting the use of RNA-based tests to stratify breast cancer patients – Are they all the same?
Miguel Martin, Madrid, Spain
- 14:15 How can we ensure quality and safety for biomarkers used in breast cancer?
Frédérique Penault-Llorca, Clermont-Ferrand, France
- 14:30 Evaluating cost effectiveness of molecular diagnostics
Adrian Towse, London, UK
- 14:45 Ensuring quality for patients
Eva Schumacher-Wulf, Kronberg, Germany
- 14:55 Conclusions
Martine Piccart, Brussels, Belgium
- 15:05 Panel discussion

